58 results
8-K
EX-10.2
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
permission for a qualified accountant nominated by CRH to inspect and audit those accounts and records and, to the extent that they relate
8-K
EX-99.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
announces, presents, or publishes from time to time may change as more data and information become available (or are updated based upon audit, validation … audit, validation and verification procedures of the data/information commonly performed for clinical trials) that could result in material changes
8-K
EX-10.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
of internationally recognized standing selected by ProBioGen, to inspect and audit, during normal business hours and upon at least [***]’ written notice … to inspect or audit records more than once annually. If such accounting firm concludes that there is a negative discrepancy between a statement of ValenzaBio
8-K
EX-10.1
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
audit, claim, dispute, examination, investigation, or other Proceeding in respect of Tax matters.
“Tax Return” means any report, return, election … at such place or places where such records are customarily kept, upon receipt of reasonable advance notice from Seller.
Section 3.8. Audit Rights
8-K
EX-99.4
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
in the United States of America.
Basis for Opinion
We conducted our audit in accordance with auditing standards generally accepted in the United States … of America (“GAAS”). Our responsibilities under those standards are further described in the Auditor’s Responsibilities for the Audit of the Financial
8-K
vjx5bqdq 7hc21hgc
26 Jun 24
Submission of Matters to a Vote of Security Holders
4:23pm
DEFM14A
aujq 68tfkv0c3z
4 Jun 24
Proxy related to merger
8:00am
PREM14A
xotc2tp1e7w
17 May 24
Preliminary proxy related to merger
4:36pm
DEFA14A
l3oh0yyv hgax
11 Apr 24
Additional proxy soliciting materials
8:10am
8-K
EX-2.1
p4dh6nq faa56xua4
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-99.2
q2vp7 w2m
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-10.4
nm17rgt m39
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am